Amneal Launches Amicar Rival With CGT Exclusivity

Also Introduces US Rivals To Revatio And Carafate

After receiving FDA approval for its generic aminocaproic acid with 180 days of exclusivity under the agency’s Competitive Generic Therapy pathway, Amneal has launched the rival to Amicar. At the same time, it has also begun selling a generic version of Revatio and has also claimed the first generic rival to Carafate.

Exclusive_Stamp
Amneal will enjoy 180 days of exclusivity for its Amicar rival • Source: Shutterstock

More from Products

More from Generics Bulletin